Efficacy and safety of pazopanib as a subsequent treatment after failure of other targeted agents in patients with metastatic renal cell carcinoma (mRCC).
Jiahuai Tan
No relevant relationships to disclose
Lance K. Heilbrun
No relevant relationships to disclose
Joseph A. Fontana
No relevant relationships to disclose
Daryn Smith
No relevant relationships to disclose
Elisabeth I. Heath
No relevant relationships to disclose
Karen Baranowski
No relevant relationships to disclose
Ulka N. Vaishampayan
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline